
Sign up to save your podcasts
Or


Neha J. Pagidipati, MD, FACC, JACC Associate Editor and Subodh Verma MD, PhD explore a secondary analysis of the SELECT trial, a landmark study investigating the cardiovascular benefits of semaglutide in people with obesity or overweight without diabetes.
By American College of Cardiology4.2
162162 ratings
Neha J. Pagidipati, MD, FACC, JACC Associate Editor and Subodh Verma MD, PhD explore a secondary analysis of the SELECT trial, a landmark study investigating the cardiovascular benefits of semaglutide in people with obesity or overweight without diabetes.

138 Listeners

319 Listeners

503 Listeners

897 Listeners

20 Listeners

30 Listeners

3,383 Listeners

136 Listeners

1,150 Listeners

63 Listeners

39 Listeners

197 Listeners

92 Listeners

377 Listeners

435 Listeners